Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a lot more than 100%. Take, for example Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). Its share price is already up an impressive 155% in the last twelve months. It's up an even more impressive 194% over the last quarter. We'll need to follow Salarius Pharmaceuticals for a while to get a better sense of its share price trend, since it hasn't been listed for particularly long.

Check out our latest analysis for Salarius Pharmaceuticals

Given that Salarius Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last year Salarius Pharmaceuticals saw its revenue grow by 56%. That's stonking growth even when compared to other loss-making stocks. And the share price has responded, gaining 155% as we previously mentioned. It's great to see strong revenue growth, but the question is whether it can be sustained. The strong share price rise indicates optimism, so there may be a better opportunity for buyers as the hype fades a bit.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

Salarius Pharmaceuticals shareholders should be happy with the total gain of 155% over the last twelve months. A substantial portion of that gain has come in the last three months, with the stock up 194% in that time. Demand for the stock from multiple parties is pushing the price higher; it could be that word is getting out about its virtues as a business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Salarius Pharmaceuticals has 7 warning signs (and 3 which shouldn't be ignored) we think you should know about.

We will like Salarius Pharmaceuticals better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you decide to trade Salarius Pharmaceuticals, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.